See more : Sparinvest INDEX Mellem Risiko KL (SPVIMRKL.CO) Income Statement Analysis – Financial Results
Complete financial analysis of DICE Therapeutics, Inc. (DICE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DICE Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shalimar Wires Industries Limited (SHALIWIR.BO) Income Statement Analysis – Financial Results
- Penguin International Limited (BTM.SI) Income Statement Analysis – Financial Results
- Hydratec Industries NV (HYDRA.AS) Income Statement Analysis – Financial Results
- Bank of Zhengzhou Co., Ltd. (002936.SZ) Income Statement Analysis – Financial Results
- Mangalore Refinery and Petrochemicals Limited (MRPL.BO) Income Statement Analysis – Financial Results
DICE Therapeutics, Inc. (DICE)
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.13M | 863.00K | 5.78M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 1.13M | 863.00K | 5.78M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 62.56M | 36.51M | 19.58M | 15.72M |
| General & Administrative | 25.66M | 12.22M | 5.00M | 3.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.66M | 12.22M | 5.00M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Cost & Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Interest Income | 5.21M | 136.00K | 139.00K | 635.00K |
| Interest Expense | 679.00K | 174.00K | 13.00K | 26.00K |
| Depreciation & Amortization | 5.21M | 136.00K | 836.00K | 1.34M |
| EBITDA | -83.01M | -47.47M | -22.89M | -12.21M |
| EBITDA Ratio | 0.00% | -4,219.29% | -2,651.80% | -211.36% |
| Operating Income | -88.22M | -47.60M | -23.72M | -13.55M |
| Operating Income Ratio | 0.00% | -4,231.38% | -2,748.67% | -234.58% |
| Total Other Income/Expenses | 4.33M | -1.36M | -18.00K | 609.00K |
| Income Before Tax | -83.89M | -48.96M | -23.74M | -12.94M |
| Income Before Tax Ratio | 0.00% | -4,351.91% | -2,750.75% | -224.03% |
| Income Tax Expense | -2.22M | -487.00K | 13.00K | 26.00K |
| Net Income | -81.66M | -48.47M | -23.75M | -12.96M |
| Net Income Ratio | 0.00% | -4,308.62% | -2,752.26% | -224.48% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39.40M | 12.38M | 23.23M | 23.23M |
| Weighted Avg Shares Out (Dil) | 39.40M | 12.38M | 23.23M | 23.23M |
Lilly Completes Acquisition of DICE Therapeutics
Lilly Announces Extension of Tender Offer to Acquire DICE
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Source: https://incomestatements.info
Category: Stock Reports